Haleon (HLN) Net Margin (2021 - 2023)

Haleon (HLN) recorded quarterly Net Margin of 13.05% in Q4 2023, up 20.47% on a QoQ basis from 10.83% in Q2 2023, and down 9.0% year-over-year from 14.34% in Q4 2022.

Haleon (HLN) Net Margin (2021 - 2023) Analysis & Trends

Haleon has disclosed Net Margin across 3 years of filings, most recently posting 13.05% for Q4 2023.

  • Quarterly Net Margin fell 9.0% year-over-year to 13.05% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 12.5% (changed N/A YoY) and the FY2025 annual result came in at 15.11%, up 228.0% from the prior year.
  • Net Margin grew to 13.05% in Q4 2023, from 10.83% in the prior quarter.
  • Over five years, Net Margin peaked at 25.38% in Q4 2021 and troughed at 10.83% in Q2 2023.
  • A 3-year average of 15.08% and a median of 13.05% in 2023 frame the typical range for Net Margin.
  • Annual changes were most pronounced in 2022 — Net Margin tumbled 1225 bps — and 2023, when it declined 9 bps.
  • Tracing HLN's Net Margin over 3 years: stood at 25.38% in 2021, then plunged by 48 bps to 13.13% in 2022, then slipped by 1 bps to 13.05% in 2023.
  • Business Quant data shows HLN's Net Margin at 13.05% in Q4 2023, 10.83% in Q2 2023, and 13.03% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 9.19%
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 26.57%
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 35.18%
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 2.94%
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 24.30%
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 4.16%
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -168.42%
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -15.15%
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 31.38%
10 Haleon 1.09 Bn -773.69 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 13.05%
Jun 30, 2023 10.83%
May 3, 2023 13.03%
Dec 31, 2022 13.13%
Dec 31, 2021 25.38%